CRISM Therapeutics Corporation (AIM:CRTX)
London · Delayed Price · Currency is GBP · Price in GBX 9.53
-0.22 (-2.26%)
Sep 25, 2026, 1:49 PM GMT
CRISM Therapeutics Balance Sheet
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2.27 | 1.13 | 1.28 | 0 | 2.89 | 4.93 |
Cash & Short-Term Investments | 2.27 | 1.13 | 1.28 | 0 | 2.89 | 4.93 |
Cash Growth | 550.14% | -12.01% | 128100.00% | -99.97% | -41.42% | 141.49% |
Accounts Receivable | - | - | - | 0.01 | - | - |
Other Receivables | 0.51 | 0.24 | 0.05 | - | - | 0.08 |
Receivables | 0.51 | 0.24 | 0.05 | 0.01 | - | 0.08 |
Prepaid Expenses | - | 0.29 | 0.36 | - | 0.05 | - |
Other Current Assets | - | - | - | - | 20.91 | 18.05 |
Total Current Assets | 2.78 | 1.66 | 1.69 | 0.01 | 23.85 | 23.07 |
Property, Plant & Equipment | 0.03 | 0.04 | 0.05 | 0.07 | - | - |
Other Intangible Assets | 0.11 | 0.1 | 0.07 | 0.05 | - | - |
Total Assets | 2.92 | 1.8 | 1.82 | 0.13 | 23.85 | 23.07 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.34 | 0.2 | 0.03 | - | 0.11 | 0.71 |
Accrued Expenses | - | 0.09 | 0.14 | 0.01 | 0.51 | - |
Short-Term Debt | - | - | - | 0.3 | - | - |
Current Portion of Long-Term Debt | - | - | - | 0.09 | - | - |
Other Current Liabilities | - | 0.09 | 0.17 | 0.02 | 0.15 | 0.12 |
Total Current Liabilities | 0.34 | 0.38 | 0.34 | 0.42 | 0.76 | 0.83 |
Long-Term Debt | - | - | - | 0.3 | - | - |
Total Liabilities | 0.34 | 0.38 | 0.34 | 0.73 | 0.76 | 0.83 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 70.69 | 68.07 | 66.23 | - | 67.05 | 59.41 |
Additional Paid-In Capital | 3.36 | 3.36 | 3.36 | - | 3.55 | 3.16 |
Retained Earnings | -6.01 | -3.67 | -1.21 | -0.6 | -33.64 | -27.71 |
Comprehensive Income & Other | -65.47 | -66.34 | -66.9 | - | -13.88 | -12.63 |
Shareholders' Equity | 2.58 | 1.42 | 1.48 | -0.6 | 23.09 | 22.24 |
Total Liabilities & Equity | 2.92 | 1.8 | 1.82 | 0.13 | 23.85 | 23.07 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | - | - | 0.7 | - | - |
Net Cash (Debt) | 2.27 | 1.13 | 1.28 | -0.7 | 2.89 | 4.93 |
Net Cash Growth | 550.14% | -12.01% | - | - | -41.42% | 141.49% |
Net Cash Per Share | 0.05 | 0.03 | 0.04 | -43.50 | 0.33 | 0.57 |
Filing Date Shares Outstanding | 54.54 | 51.74 | 32.68 | 8.71 | 8.71 | 8.62 |
Total Common Shares Outstanding | 54.54 | 51.74 | 32.68 | 8.71 | 8.71 | 8.62 |
Working Capital | 2.44 | 1.28 | 1.35 | -0.41 | 23.09 | 22.24 |
Book Value Per Share | 0.05 | 0.03 | 0.05 | -0.07 | 2.65 | 2.58 |
Tangible Book Value | 2.47 | 1.31 | 1.4 | -0.65 | 23.09 | 22.24 |
Tangible Book Value Per Share | 0.05 | 0.03 | 0.04 | -0.07 | 2.65 | 2.58 |
Machinery | - | 0.16 | 0.16 | 0.16 | - | - |